Introduction

Overview of drug resistance mechanisms
Elucidation of cellular resistance mechanisms holds the promise of leading to better treatments for cancer patients. The past few years have seen notable growth in the identification of resistance mechanisms. Most of the known mechanisms associated with small molecules can be categorized by the schema shown in Figure 1 . Resistance mechanisms can operate to either prevent agents from entering cells, as in loss of plasma membrane carriers for nucleoside analogs (hENT1), antifolates (RFC1) and cisplatin (CTR1), or enhance their extrusion, as exemplified by energy-dependent pumps such as ABC transporters (Pgp, MRPs, ABCG2) and ATB7b, a copper pump that is able to mediate the extrusion of cisplatin. As assessed in drug-resistant cell lines, ATP-dependent pumps appear to be most relevant to agents that enter cells by passive diffusion, such as natural product chemotherapeutic agents. On the other hand, cells are more likely to acquire resistance to agents that require plasma membrane carriers by decreasing the expression of the carriers, as opposed to deploying energydependent pumps for these agents or their metabolites.
Once inside the cell, the activity of drugs that require activation can be impaired by loss of specific enzymatic activities involved in their metabolic activation, as in the case of the metabolism of nucleoside analogs to cytotoxic nucleotide analogs (e.g., AraC). Certain agents can also be enzymatically inactivated, as in the case of methylation of thiopurine nucleobase analogs by thiopurine methyltransferase (TPMT). Cellular targets can also be altered, either by increased expression levels, or by mutations, such that they are less susceptible to inhibition, as in the case of camptothecins (topoisomerase I), epipodophyllotoxins (toposimerase II) antifolates (dihydrofolate reductase), fluoropyrimidines (thymidylate synthetase) and Gleevec (BCR-ABL). Once a cellular target is damaged, resistance factors can attenuate the capacity of a cell to undergo apoptosis (i.e., loss of p53 and cell cycle checkpoints). Another class of resistance involves factors that influence the ability of the cell to repair damaged macromolecules. Examples of this include loss of mismatch repair enzymes, which appears to confer resistance to fluoropyrimidines, or inactivation of MGMT, which confers enhanced sensitivity to certain alkylating agents. Each of these classes of resistance mechanisms is described in this issue.
Drug resistance is a manifestation of cancer
As many of the best-characterized drug resistance mechanisms were elucidated from investigations of cell lines made highly resistant by stepwise selection in drug, and largely involve factors that influence the extent to which agents interact with their immediate cellular targets (mechanisms 1 and 2 in Figure 1 ), focusing on these mechanisms tends to lead to a 'drug-centric' perspective, and it is easy to lose track of the fact that clinical drug resistance is a manifestation of cancer. An informative way to illustrate this notion is to point out the clinical observation that while it is anticipated that even highly sensitive cancers, such as leukemias, lymphomas and small cell lung cancer, will frequently become resistant during the course of treatment, it is also anticipated that the patient's drug-sensitive tissues (i.e., bone marrow and mucosal surfaces of the alimentary tract) will not only not become resistant, but may in fact become increasingly depleted during therapy and eventually limit treatment options (Chu and DeVita, 2001 ). Thus, the somatic mutations and genomic plasticity associated with cancer are the foundation of drug resistance, be it acquired or intrinsic. In the circumstance of normal tissues, resistance does not arise, because the mutation rate is too low to permit defects in the genetic elements that control sensitivity.
Apoptotic competence and cell growth
An observation that pertains to the relationship between growth and drug sensitivity stems from cell lines made highly resistant in vitro. Cell lines obtained by exposure to specific agents may exhibit cross-resistance to closely related agents, or may exhibit a multidrug-resistant phenotype, as occurs when efflux pumps such as Pgp are induced, or when cell lines obtained by growth in the presence of one DNA-damaging agent become tolerant of other DNA-damaging agents. However, even extremely resistant cell lines are not significantly pan-resistant. That is, drug-selected cell lines are never cross-resistant to all chemotherapeutic agents. Instead, the acquired resistance phenotype of selected cells typically reflects the operation of a few dominant resistance factors that involve mechanisms '1' or '2', and to a lesser extent '3', but probably not mechanism 4 (Figure 1 ). If drug-mediated cell death is considered to occur by way of apoptosis, and accumulating evidence indicates that this is the case, this in vitro observation suggests that even under intense drug pressure cells are unable to render themselves incompetent in apoptosis. This would appear to reflect a close relationship between growth and apoptosis. Stated another way, elimination of the basic machinery of apoptosis does not appear to be compatible with cell growth, even in tissue culture cells. If drug-induced cell death occurs via the mitochondrial pathway, then this phenomenon is understandable in view of the essential non-cell death-related functions possessed by mitochondrial components involved in apoptosis.
Intrinsic resistance and somatic mutations
Another way to view the relationship between cancer and chemosensitivity is to consider intrinsic sensitivity from the point of view of cancer development. Cancers can be categorized as either intrinsically sensitive, as are most childhood cancers, and leukemias and lymphomas in adults, or intrinsically resistant, as are many epithelial tumors in adults. Intrinsic chemosensitivity reflects distinct etiological pathways. Intrinsically sensitive tumors arise quickly, do not have recognizable premalignant states, and are characterized by relatively simple chromosomal abnormalities, such as translocations involving dominantly acting transcription factors and antiapoptotic proteins (Table 1) . Examples of these types of translocations include myc/IgH, EWS-ETS, PAX-3-FKHR, in Burkitt's lymphoma, Ewings sarcoma and alveolar rhabdomyosarcoma, respectively, Bcl-2/IgH in follicular lymphomas, and BCR-ABL in chronic myelogenous leukemia. On the other hand, cancers that arise after prolonged premalignant states have ample opportunity to sustain multiple genetic 'hits', are characterized by genetic instability and have complex karyotypes (Knudson, 2001) . This is the case with most common epithelial cancers in adults, such as the lung and colon, and these cancers tend to be intrinsically resistant. This is a consequence of the acquisition of genetic lesions that inactivate tumor suppressors involved in the regulation of apoptotic pathways, as well as activating dominant-acting genes.
Targeted therapy and resistance
Resistance associated with several newer agents are also discussed in this issue. What can insights obtained from investigations of standard cytotoxic agents teach us about the application of 'targeted chemotherapeutics' that are moving into the clinic? From the point of view of small molecules, the answer is probably quite a bit. Resistance mechanisms associated with these agents will undoubtedly be reminiscent of mechanisms that are well described for older chemotherapeutic agents. This is illustrated by resistance mechanisms associated with the BCR-ABL kinase inhibitor STI571. Known mechanisms deduced from the analysis of patient samples indicate the frequent involvement of diverse point mutations in the BCR-ABL kinase domain that render it unable to bind to STI571 and increased copy numbers of BCR-ABL. In vitro studies suggest the possibility that the operation of plasma membrane efflux pumps such as Pglycoprotein may also contribute (i.e., mechanisms 1 and 2 in Figure 1 ; discussed in Shah and Sawyers). Identification of these mechanisms in the short period of time in which this agent has been employed has helped to direct the development of improved treatments for CML, and also highlights the notion that a hallmark of highly targeted therapy is highly targeted resistance mechanisms.
In the case of biological modalities, such as Rituximab and Herceptin, the spectrum of cellular adaptations associated with resistance is likely to be distinct from those associated with small molecules, and should be highly informative. This is discussed in the review on Rituxamib in this issue. With these agents, as with older agents, it is hoped that insights into resistance mechanisms will engender better treatments for cancer patients.
